Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

IMPORTANCE: Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial. The benefits and risks associated with ticagrelor vs clopidogrel in routine practice merits atte...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA
Hlavní autoři: You, Seng Chan, Rho, Yeunsook, Bikdeli, Behnood, Kim, Jiwoo, Siapos, Anastasios, Weaver, James, Londhe, Ajit, Cho, Jaehyeong, Park, Jimyung, Schuemie, Martijn, Suchard, Marc A., Madigan, David, Hripcsak, George, Gupta, Aakriti, Reich, Christian G., Ryan, Patrick B., Park, Rae Woong, Krumholz, Harlan M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2020
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7592033/
https://ncbi.nlm.nih.gov/pubmed/33107944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.16167
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky